---
title: "Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | SNSE Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286556671.md"
description: "Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | SNSE Stock News"
datetime: "2026-05-15T03:30:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286556671.md)
  - [en](https://longbridge.com/en/news/286556671.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286556671.md)
---

# Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | SNSE Stock News

Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | SNSE Stock News

### Related Stocks

- [SNSE.US](https://longbridge.com/en/quote/SNSE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)

## Related News & Research

- [Sensei Biotherapeutics reports $170.2M Q1 net loss, $202.8M cash position](https://longbridge.com/en/news/286559285.md)
- [Capricor publishes investor presentation on deramiocel Duchenne muscular dystrophy program](https://longbridge.com/en/news/287222906.md)
- [BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts | ONC Stock News](https://longbridge.com/en/news/287198763.md)
- [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md)
- [Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis](https://longbridge.com/en/news/286899753.md)